Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Net Income towards Common Stockholders (2017 - 2020)

Historic Net Income towards Common Stockholders for Cogent Biosciences (COGT) over the last 4 years, with Q4 2020 value amounting to -$11.4 million.

  • Cogent Biosciences' Net Income towards Common Stockholders fell 59564.65% to -$11.4 million in Q4 2020 from the same period last year, while for Sep 2021 it was -$11.4 million, marking a year-over-year increase of 8334.87%. This contributed to the annual value of -$82.1 million for FY2020, which is 15776.71% down from last year.
  • As of Q4 2020, Cogent Biosciences' Net Income towards Common Stockholders stood at -$11.4 million, which was down 59564.65% from -$57.2 million recorded in Q3 2020.
  • Over the past 5 years, Cogent Biosciences' Net Income towards Common Stockholders peaked at $2.3 million during Q4 2019, and registered a low of -$57.2 million during Q3 2020.
  • For the 4-year period, Cogent Biosciences' Net Income towards Common Stockholders averaged around -$10.9 million, with its median value being -$8.0 million (2018).
  • In the last 5 years, Cogent Biosciences' Net Income towards Common Stockholders surged by 12669.07% in 2019 and then tumbled by 59564.65% in 2020.
  • Over the past 4 years, Cogent Biosciences' Net Income towards Common Stockholders (Quarter) stood at -$6.7 million in 2017, then decreased by 28.33% to -$8.6 million in 2018, then skyrocketed by 126.69% to $2.3 million in 2019, then tumbled by 595.65% to -$11.4 million in 2020.
  • Its Net Income towards Common Stockholders stands at -$11.4 million for Q4 2020, versus -$57.2 million for Q3 2020 and -$7.4 million for Q2 2020.